Lancer Healthcare

Wegovy (semaglutide) is a once-weekly prescription injection—and newly approved oral tablet—used for chronic weight management in adults and adolescents (12+) with obesity or overweight, when combined with diet and exercise. It acts as a GLP-1 receptor agonist to mimic hormones that regulate hunger, reducing appetite and caloric intake. Key Details About Wegovy

• Purpose: Long-term weight management (BMI $\geq$30, or $\geq$27 with weight-related conditions like hypertension or type 2 diabetes).
• Dosage & Administration: Self-administered weekly injection (subcutaneous) or daily oral tablet. Dosage is gradually increased over 16 weeks to reduce side effects.
• Effectiveness: Studies show users can lose, on average, about  to  of their body weight.
• Active Ingredient: Semaglutide.
• Side Effects: Commonly gastrointestinal, including nausea, vomiting, diarrhea, constipation, and stomach pain.

RANIBIZUMAB belongs to the group of medicines called anti-neovascularisation agents used to treat eye diseases causing vision impairment, such as neovascular (wet) age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, proliferative diabetic retinopathy, and choroidal neovascularization. It is also used to treat retinopathy of prematurity in babies born prematurely. RANIBIZUMAB contains Ranibizumab, a vascular endothelial growth factor A (VEGF-A) antagonist. It binds to VEGF-A (a protein that causes abnormal blood vessel growth and swelling, leading to vision impairment) present in the eyes, blocks its action, and prevents abnormal growth and swelling. It helps stabilise and improve vision. Let the doctor know if you are allergic to any components in RANIBIZUMAB. Consult the doctor if you are pregnant, think you may be pregnant or planning for pregnancy. RANIBIZUMAB is not recommended during breastfeeding. Keep your doctor informed about your health condition and medications to rule out any side effects/interactions.